Skip to content
OpenCapital
Get started

Theriva Biologics TOVX Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$300.0KIn line
EPS-$0.05In line
Revenue estimate$300.0K
EPS estimate-$0.05

Next report

Aug 12, 2026 (In 2 weeks)
Revenue estimate$300.0K
EPS estimate-$0.06

Versus estimates

Revenue

Q1 2026$300.0KIn line
Q4 2024$154.0K

Diluted EPS

Q1 2026-$0.05In line
Q4 2025$1.85Beat by $2.29Q3 2025-$0.45Miss by $0.07Q2 2025-$1.93Miss by $1.55Q1 2025-$1.55Beat by $2.64Q4 2024-$3.30Beat by $3.06

Ask the moment Theriva Biologics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Theriva Biologics report Q1 2026 earnings?
Theriva Biologics (TOVX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Theriva Biologics's Q1 2026 revenue and EPS?
Theriva Biologics reported revenue of $300.0K and eps of $-0.05 for Q1 2026.
Did Theriva Biologics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $300.0K by -. EPS beat the consensus estimate of $-0.05 by $0.00.
How did Theriva Biologics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 96.8% from $-1.55.
Where can I find Theriva Biologics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-055679) and the 10-Q periodic report (0001104659-26-055689) directly on SEC EDGAR. The filing index links above go to sec.gov.